DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application

Related Keywords

China , Germany , Munich , Bayern , Berlin , Nanjing , Jiangsu , Amsterdam , Noord Holland , Netherlands , Renhong Tang , Jason Bao , Halle Saale , Sophia Hergenhan , Manuela Bader , Jian Hou , Michael Schaeffer , Simcere Pharmaceutical Group , Drug Administration , Trophic Communications , Simcere Pharmaceutical Group Ltd , Distribution Services , National Medical Products Administration , News Service , China Center , Vivoryon Therapeutics , Simcere Announce , Chinese Clinical Trial Application , Euronext Amsterdam , Drug Evaluation , Clinical Trial Application , Greater China , Executive Vice President , Chief Business Officer , Fast Track , Pharmaceutical Group , Simcere Pharmaceutical Group Limited , Board Secretary , Corporate News , Regulatory Announcements , Unofficial Market , Dgap , News , Vivoryon , Herapeutics , Simcere , Nnounce , Approval , Chinese , Linical , Trial , Application , Aroglutamstat , Im0408 , Q912 , Patients , Lzheimer , Disease ,